Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) Equity Average (2021 - 2025)

Historic Equity Average for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $9.0 million.

  • Coeptis Therapeutics Holdings' Equity Average rose 28517.84% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 28517.84%. This contributed to the annual value of $2.3 million for FY2024, which is 1112.72% down from last year.
  • Coeptis Therapeutics Holdings' Equity Average amounted to $9.0 million in Q3 2025, which was up 28517.84% from $7.3 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' 5-year Equity Average high stood at $9.0 million for Q3 2025, and its period low was -$1.6 million during Q4 2021.
  • Over the past 5 years, Coeptis Therapeutics Holdings' median Equity Average value was $2.3 million (recorded in 2022), while the average stood at $2.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 15168.4% in 2024, then skyrocketed by 356836.42% in 2025.
  • Coeptis Therapeutics Holdings' Equity Average (Quarter) stood at -$1.6 million in 2021, then skyrocketed by 449.35% to $5.6 million in 2022, then crashed by 75.82% to $1.4 million in 2023, then soared by 226.94% to $4.4 million in 2024, then skyrocketed by 103.36% to $9.0 million in 2025.
  • Its Equity Average was $9.0 million in Q3 2025, compared to $7.3 million in Q2 2025 and $5.7 million in Q1 2025.